Last reviewed · How we verify
AG2001
AG2001 is a small molecule that targets the SARS-CoV-2 main protease.
AG2001 is a small molecule that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | AG2001 |
|---|---|
| Sponsor | Ahn-Gook Pharmaceuticals Co.,Ltd |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
AG2001 works by binding to the SARS-CoV-2 main protease, thereby inhibiting the viral replication. This mechanism of action is crucial in treating COVID-19. AG2001 has shown promise in preclinical studies.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AG2001 CI brief — competitive landscape report
- AG2001 updates RSS · CI watch RSS
- Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI